Cresco Labs: Analyst Expectations For Q2 2021

Cresco Labs (CSE: CL) announced that they will be reporting their second quarter financials before the market opens on August 13.

Analysts have a consensus C$23.31 12-month price target on the company, via a total of 17 analysts, with 5 analysts having a strong buy rating, 11 analysts have a buy rating and a single analyst has a hold rating. The street high comes in at a C$36 price target, and the lowest target comes in at a C$13.66 price target.

13 analysts have revenue estimates for the second quarter. The mean between all 13 is $194.72 million; this number has been the same since the start of the year. The street high is $216.20 million while the lowest sits at $187 million.

8 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 50.65%, with this number being revised slightly higher from 49.25% at the start of the year. Street high goes to Beacon Securities with a 52% estimate and the lowest sits at 50%.

Onto EBITDA estimates, there are currently 131analysts who have second quarter EBITDA estimates. The mean is currently $44.56 million, with this number being lower than at the start of the year. Street high goes to ATB Capital Markets with a $47.30 million EBITDA estimate and the lowest being a $40.99 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Steadright To Conduct Multi-Phased Exploration At Historic Goundafa Polymetallic Mine

Goliath Resources Drills 10.72 g/t Gold Over 7.83 Metres At Surebet

Related News

Canaccord Genuity Raises Medipharm Labs’ Price Target To C$2.50

On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European...

Tuesday, October 6, 2020, 01:29:18 PM

TPCO Holdings: Canaccord Initiates Coverage With US$15 Price Target

This morning, Canaccord Genuity initiated coverage on The Parent Company (NEO: GRAM.u) with a US$15...

Wednesday, February 3, 2021, 04:07:00 PM

Cronos Group: Canaccord Lowers Price Target To $7 Following Poor Results

Last week, Cronos Group (TSX: CRON) reported its second quarter financial results. The company generated...

Thursday, August 12, 2021, 02:07:00 PM

Amex Exploration: PI Financial, Canaccord Reiterate Targets Following Latest Drill Results

Canaccord Genuity reiterated their 12-month price target of C$4.25 and their speculative buy rating on...

Tuesday, January 26, 2021, 04:09:00 PM

Canaccord Raises Trulieve Price Target To $75 From $60

The last two weeks have been quite an enjoyable time for U.S cannabis sector investors....

Wednesday, January 13, 2021, 02:53:00 PM